
Cat. #158320
PL1 peptide
Cat. #: 158320
Sub-type: Synthetic Peptide
Availability: Please enquire for quantities and pricing
Target: Oncofetal fibronectin extra domain-B (FN-EDB) and tenascin-C C domain (TNC-C). Relevant disease: Cancer
Function: Marker
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Tambet Teesalu ; Prakash Lingasamy
Institute: University of Tartu
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: PL1 peptide
- Alternate name: PL1, FN-EDB and TNC-C binding protein
- Research fields: Cancer;Cell biology
- Tool sub type: Synthetic Peptide
- Sequence: PPRRGLIKLKTS
- Cellular tissue localisation: Extracellular matrix
- Target: Oncofetal fibronectin extra domain-B (FN-EDB) and tenascin-C C domain (TNC-C). Relevant disease: Cancer
- Description: PL1 peptide is a short binding peptide which interacts with oncofetal fibronectin extra domain-B (FN-EDB) and tenascin-C C domain (TNC-C) which are both extracellular matrix proteins present in a tumour microenvironment. The targets of PL1 are nearly absent in normal adult tissues making them indicative of solid tumour tissues. It has been shown that this dual-targeted peptide can be used for robust and specific delivery of imaging agents and therapeutic payloads to solid tumours.
- Function: Marker
- Expression system: Synthetic
Handling
- Shipping conditions: Dry Ice
Target Details
- Target: Oncofetal fibronectin extra domain-B (FN-EDB) and tenascin-C C domain (TNC-C). Relevant disease: Cancer
Related Tools
- Related tools: PL2 Peptide ; PL3 Peptide
References
- Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)



